PRNewswire

Preclinical data in type 1 diabetes organoid model demonstrate MTX-101 can reestablish functionality of pancreatic beta cells Phase 1 clinical study underway to evaluate MTX-101 in healthy adults and patients with celiac disease and T1D SEATTLE, Nov. 5, 2024 /PRNewswire/ — Mozart Therapeutics,

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: